{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:43:53Z","timestamp":1792215833750,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinre.2026.102899","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:36:05Z","timestamp":1786034165000},"page":"102899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors in liver transplant recipients with diabetes"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4661-9629","authenticated-orcid":false,"given":"Alessandra","family":"Mazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sultanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Rebiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Scatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bourron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2026.102899_bib0001","doi-asserted-by":"crossref","unstructured":"Brodosi, L.; Petta, S.; Petroni, M.L.; Marchesini, G.; Morelli, M.C.; Management of diabetes in candidates for liver transplantation and in transplant recipients transplantation. 2022;106(3):462-478. doi: 10.1097\/TP.0000000000003867.","DOI":"10.1097\/TP.0000000000003867"},{"issue":"6","key":"10.1016\/j.clinre.2026.102899_bib0002","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post liver transplant: results of the NIDDK long term follow-up study","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinre.2026.102899_bib0003","article-title":"Progress of new-onset diabetes after liver and kidney transplantation","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne) online"},{"key":"10.1016\/j.clinre.2026.102899_bib0004","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/jcm10051045","article-title":"A time-based meta-analysis on the incidence of new onset diabetes after liver transplantation","volume":"10","author":"Chin","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinre.2026.102899_bib0005","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinre.2026.102899_bib0006","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinre.2026.102899_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"Castellana","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinre.2026.102899_bib0008","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon- like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinre.2026.102899_bib0009","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2019.01.001","article-title":"Effects of sodium-glucose co-transporter 2 inhibitor monotherapy on weight changes in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis","volume":"41","author":"Wang","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinre.2026.102899_bib0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose co-transporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinre.2026.102899_bib0011","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/dom.13620","article-title":"The renoprotective effects of sodium-glucose co-transporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney dis- ease: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinre.2026.102899_bib0012","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102899_bib0013","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.121.057934","article-title":"Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose Co-transporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial","volume":"145","author":"Lam","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.clinre.2026.102899_bib0014","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/oby.2011.152","article-title":"Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes","volume":"19","author":"Sathyanarayana","year":"2011","journal-title":"Obes (Silver Spring)"},{"key":"10.1016\/j.clinre.2026.102899_bib0015","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinre.2026.102899_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005325","article-title":"Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta- analysis of randomised controlled trials on patients with type 2 diabetes","volume":"4","author":"Gluud","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinre.2026.102899_bib0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/liv.14799","article-title":"Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: a real-world data analysis","volume":"41","author":"Colosimo","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2026.102899_bib0018","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapaglfozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"10.1016\/j.clinre.2026.102899_bib0019","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clinre.2026.102899_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18470","article-title":"Sodium-glucose cotransporter 2 inhibitors and serious liver events in patients with cirrhosis","volume":"8","author":"Abu-Hammour","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinre.2026.102899_bib0021","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/LVT.0000000000000233","article-title":"Utility of glucagon-like peptide 1 receptor agonists as anti-obesity medications in liver transplant recipients","volume":"30","author":"Richardson","year":"2024","journal-title":"Liver Transpl"},{"issue":"10S","key":"10.1016\/j.clinre.2026.102899_bib0022","doi-asserted-by":"crossref","first-page":"S1006","DOI":"10.14309\/01.ajg.0000954912.01880.7c","article-title":"S1318 Semaglutide is effective in achieving weight loss in liver transplant recipients","volume":"118","author":"Chow","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2026.102899_bib0023","doi-asserted-by":"crossref","unstructured":"Atthota S, Joyal K, Cote M, et al. Modern glucose-lowering drugs in liver transplant recipients: improvement in weight, glycemic control, and potentially allograft steatosis. Frontiers in Transplantation. 2:1223169. doi: 10.3389\/frtra.2023.1223169.","DOI":"10.3389\/frtra.2023.1223169"},{"issue":"1","key":"10.1016\/j.clinre.2026.102899_bib0024","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1210\/clinem\/dgad395","article-title":"Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia","volume":"109","author":"Pena","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.clinre.2026.102899_bib0025","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/TP.0000000000004945","article-title":"Glucagon-like peptide 1 receptor agonists and cardiovascular outcomes in solid organ transplant recipients with diabetes mellitus","volume":"108","author":"Dotan","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.clinre.2026.102899_bib0026","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s13300-020-00786-1","article-title":"A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation","volume":"11","author":"Thangavelu","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinre.2026.102899_bib0027","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/dom.13964","article-title":"Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: a retrospective study","volume":"22","author":"Singh","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinre.2026.102899_bib0028","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1111\/dom.15769","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients","volume":"26","author":"Zheng","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinre.2026.102899_bib0029","article-title":"Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors sec","volume":"16","author":"Grancini","year":"2025","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.clinre.2026.102899_bib0030","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1097\/TP.0000000000005361","article-title":"Impact of glucagon-like peptide-1 receptor agonists on metabolic health in liver transplant recipients","volume":"109","author":"Yakubu","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.clinre.2026.102899_bib0031","doi-asserted-by":"crossref","unstructured":"Mantovani, A.; Byrne, C.D.; Targher, G.; Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. 2022. DOI:https:\/\/doi.org\/10.1016\/S2468-1253(21)00261-2.","DOI":"10.1016\/S2468-1253(21)00261-2"},{"key":"10.1016\/j.clinre.2026.102899_bib0032","unstructured":"https:\/\/www.sfdiabete.org\/recommandations\/autres-recommandations\/prise-de-position-ada-easd-sur-la-prise-en-charge-de."},{"issue":"3","key":"10.1016\/j.clinre.2026.102899_bib0033","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2337\/diacare.27.3.805","article-title":"Alan Wilkinson International Expert panel on new-onset diabetes after transplantation. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist's view","volume":"27","author":"Davidson","year":"2004","journal-title":"Diabetes Care"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:18:35Z","timestamp":1792214315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126001452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2210740126001452"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102899","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors in liver transplant recipients with diabetes","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102899"}}